Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer

Publication Date: August 8, 2016
Last Updated: December 16, 2022

Assessment

All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynecologic oncologist prior to initiation of therapy to determine whether they are candidates for primary cytoreductive surgery (PCS). ( EB , H , B , M )
3336

Treatment

Women who have a high perioperative risk profile or a low likelihood of achieving cytoreduction to <1 cm (ideally to no visible disease) should receive NACT. ( EB , H , H , M )
3336

Overview

Title

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer

Authoring Organizations